SAMe

Phase 2Small molecule

IIndiana University

SAMe is one of 49 small molecule programs targeting Treatment-resistant Bipolar Depression. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Treatment-Resistant Bipolar DepressionCompleted

CirrhosisRecruiting

Treatment-Resistant Bipolar DepressionPreclinical

Completed

CirrhosisPhase 2

Recruiting

Competition

Competitive Landscape

74 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Emtriva

Gilead

Approved

1 2

Vemlidy

Gilead

Approved

1 3

Actos

Takeda

Approved

1 4

Tyzeka

Novartis

Approved

1 5

Xifaxan

SSalix

Approved

6 6

Vancocin

HHikma Pharmaceuticals LLC

Approved

1 7

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

1 8

Bumex

VValidus Pharmaceuticals

Phase 3

1 9

Crestor

AstraZeneca

Phase 2

2 10

Savaysa

Daiichi Sankyo

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Cirrhosis

NCT04250259

Clinical

Trials by Indication[1]

Cirrhosis1 trial

SAMe Trial for Patients With Alcoholic Cirrhosis

Recruiting·IIndiana University·Phase 2·NCT04250259·196 enrolled

Alcoholic Fatty Liver Disease1 trial

Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group

Completed·AAbbott·Phase 3·NCT01754714·108 enrolled

Treatment-resistant Bipolar Depression1 trial

A Trial of SAMe for Treatment-Resistant Bipolar Depression

Completed·MMclean Hospital·N/A·NCT00762268·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SAMe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAMe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAMe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIndiana University

SAMe

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Cirrhosis1 trial

Alcoholic Fatty Liver Disease1 trial

Treatment-resistant Bipolar Depression1 trial

References

Drug Info

Quick Facts

Related News